“Biological evaluation of 2,3-dioxoindolin-N-phenylacetamide derivatives as potent CDC25B and PTP1B phosphatase inhibitors”, Braz. J. Pharm. Sci., vol. 56, p. e00222, Dec. 2020, doi: 10.1590/s2175-97902019000400222.